Dyslipidemia

Approximately 2.0% of commercially insured individuals with obesity, but not diabetes, initiated semaglutide within 6 months of diagnosis.

Increases in oxidized HDL levels were linked to HFpEF in new analyses, suggesting reduced antioxidant HDL function is present in this patient population.

The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of November 18, 2025.

Semaglutide 7.2 mg achieved statistically significant and superior weight loss at 72 weeks versus placebo, hitting the Phase 3b trial's primary endpoint.

A cohort study with 14 years of follow-up found monogenic and polygenic mechanisms influencing LDL-C and incident T2D risk inversely associated.

Aspirin avoidance remained safe and did not increase thrombosis risk after LVAD implantation in patients with a history of atherosclerotic vascular conditions.

Submission of the supplemental NDA was based on positive findings from the FINEARTS-HF trial investigating finerenone for heart failure with an LVEF ≥40%.

An economic analysis highlights a cardiovascular polypill's potential to lower healthcare costs and address income-based health disparities.

Hyperuricemia was significantly linked to dyslipidemia and hypertriglyceridemia in hospitalized patients with type 2 diabetes, which remained after adjustment.

Variations in apoB concentration among Hispanic or Latino populations could provide important implications for apoB use in cardiovascular risk assessment.

Higher levels of small-particle HDL were linked with greater gray matter volume and higher cognitive capacity among middle-aged adults.

This listicle highlights 5 major approvals and 5 trial updates in cardiovascular care from 2024.

To celebrate the close of 2024, we surveyed top cardiologist on what they view as the biggest storyline in their field from the past year.

Glycemic control continues to be a major risk factor for diabetic retinopathy, while overweight, obesity, and hypertension are growing in prevalence.

A study indicates that dyslipidemia may be associated with a greater risk of psoriasis development.

Tirzepatide's approval marks the first and only prescription medicine available for adults with moderate-to-severe obstructive sleep apnea and obesity.

A study finds that individuals with low or high LDL cholesterol levels face a greater cardiovascular risk than those with medium levels.

CagriSema, a fixed dose of cagrilintide 2.4 mg and semaglutide 2.4 mg, achieved statistically significant weight loss after 68 weeks versus placebo.

Olezarsen ushers in a new era of care as the first therapy to receive FDA approval for adults with familial chylomicronemia syndrome as an adjunct to diet.

Submission of the Biologics License Application seeks approval of lerodalcibep to lower LDL-C in patients with or at risk for ASCVD and primary hyperlipidemia.

Nathan D. Wong, MPH, PhD discusses the evolution of Lp(a) in risk assessment, given its role as a genetic risk factor for cardiovascular complications.

Our Cardiology Month in Review for November 2024 spotlights the approval of acoramidis and top content from AHA 2024.

Stephen Nicholls, MBBS, PhD, provides additional insight into KRAKEN trial data and the potential of muvalaplin.

Muvalaplin, an oral treatment, reduced Lp(a) by up to 85% in a 12-week Phase 2 trial presented at AHA 2024.

Zerlasiran reduced Lp(a) by over 90% at 60 weeks with consistent efficacy and no serious drug-related adverse events, supporting its phase 3 trial progression.